Company Filing History:
Years Active: 2004
Title: The Innovative Contributions of Patrick Aebischer
Introduction
Patrick Aebischer is a prominent inventor based in Lausanne, Switzerland. He is known for his significant contributions to the field of gene therapy, particularly in relation to neurodegenerative diseases. His work has the potential to transform treatment options for conditions such as Parkinson's disease.
Latest Patents
Aebischer holds a patent for "Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases." This patent discloses and claims methods for treating or preventing neurodegenerative diseases, including Parkinson's disease. The methods involve administering a lentiviral vector that expresses GDNF, which can be human GDNF or its variants, homologs, analogs, or derivatives. This innovative approach aims to address motor deficits and promote nigrostriatal regeneration.
Career Highlights
Throughout his career, Aebischer has made significant strides in the field of biotechnology. His work at Oxford Biomedica (UK) Limited has positioned him as a leader in the development of gene therapies. His research focuses on harnessing the power of lentiviral vectors to deliver therapeutic genes effectively.
Collaborations
Aebischer has collaborated with notable colleagues, including Susan Mary Kingsman and Stuart Naylor. These partnerships have furthered research and development in gene therapy, enhancing the impact of their collective work.
Conclusion
Patrick Aebischer's innovative contributions to gene therapy represent a significant advancement in the treatment of neurodegenerative diseases. His patent and ongoing research continue to inspire hope for improved therapies in this critical area of medicine.